University of Florida startup Entrinsic Health Solutions Inc. (EHS), an innovative health sciences company, has entered into a partnership that provides for a worldwide commercial license and supply agreement for enterade®, an amino acid-based, glucose-free, electrolyte solution designed for oncology and gastrointestinal (GI) disease patients.
“We are excited about this partnership,” stated Dr. Sadasivan Vidyasagar, the principal inventor of the UF research team that developed the technology. “This was a collaborative effort. It took three teams: the scientific team, the UF Tech Licensing team, and the business team that Entrinsic gathered to move this technology forward.”
EHS and Nestlé Health Sciences (NHSc), a global leader pioneering science-based nutritional health solutions, announced its partnership is based upon EHS’s enterade® beverage. enterade® uses a patented combination of proprietary amino acid blends to help patients with GI issues related to cancer or chronic GI disease. NHSc has the right to take over the global commercialization of enterade® following the results of a clinical study of enterade® in neuroendocrine tumor (NET) patients.
“The research behind enterade® is a game-changer,” Dr. Vidyasagar said “because it extends far beyond a beneficial beverage for those suffering from dehydration.”
“What differentiates our research from others is that we’ve selected amino acids based on functional alterations associated with diseases rather than going after specific diseases,” Dr. Vidyasagar said. “Our research can produce a pipeline of products to correct functional alterations associated with various disease conditions such as GI complications associated with cancer care, cancer treatment, skin care, cystic fibrosis and asthma.”
Working with UF Innovate | Tech Licensing, EHS has exclusively licensed many technologies from Dr. Vidyasagar’s group on a worldwide basis. The company’s intellectual property includes a portfolio of issued and pending US and foreign patents.
“Dr. Vidyasagar is at the forefront of pioneering a novel platform to develop powerful new compositions addressing unmet medical needs by leveraging the diversity and synergy of amino acids to maintain or restore health across a network of pathways,” said Stephen Gatto, Chief Executive Officer of EHS.
“I believe that Dr. Vidyasagar’s work will unlock an area of science that has been vastly understudied yet has the potential to deliver some of the most revolutionary insights on a scale similar to immunotherapy,” Mr. Gatto stated further, “Without the help of UF Innovate | Tech Licensing, and the culture of entrepreneurism it has created, none of this would have been possible. Their help in securing key features of the license and continued support of Dr. Vidyasagar’s work were the twin catalyst for success. We look forward to several upcoming developments.”